ライブ
FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BPharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptationEndpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye diseaseEndpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease studyFierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibilityClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk
FierceBiotech 2025年12月5日

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

原文
本文は利用できません。元の情報源をご確認ください。